Hicin Pharmaceutical(SZ:300584) Xin Lang Cai Jing·2025-08-25 02:37Core Insights - Haichen Pharmaceutical (300584.SZ) reported a total revenue of 309 million yuan for the first half of 2025, an increase of 72.04 million yuan or 30.46% compared to the same period last year [1] - The net profit attributable to shareholders reached 29.16 million yuan, up by 4.42 million yuan or 17.87% year-on-year, marking three consecutive years of growth [1] - The net cash inflow from operating activities was 65.64 million yuan, an increase of 29.01 million yuan or 79.18% year-on-year, also achieving three consecutive years of growth [1] Financial Performance - The latest debt-to-asset ratio stands at 28.88%, a decrease of 0.47 percentage points from the same period last year [3] - The gross profit margin is reported at 85.88%, an increase of 1.74 percentage points year-on-year, continuing a three-year upward trend [3] - Return on equity (ROE) is at 2.80%, up by 0.35 percentage points compared to the previous year [3] Earnings and Ratios - The diluted earnings per share (EPS) is 0.24 yuan, an increase of 0.04 yuan or 17.90% year-on-year, marking three consecutive years of growth [3] - The total asset turnover ratio is 0.21 times, an increase of 0.04 times or 25.46% year-on-year [3] - The inventory turnover ratio is 0.53 times, up by 0.09 times or 21.32% year-on-year [3] Shareholder Structure - The number of shareholders is 26,000, with the top ten shareholders holding a total of 69.67 million shares, accounting for 58.06% of the total share capital [3] - The largest shareholder, Cao Yuping, holds 42.08% of the shares [3]